Previous 10 | Next 10 |
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA. ...
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
2023-12-25 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-14 13:38:30 ET More on Sage Therapeutics Sage Therapeutics: Postpartum Pioneer Or Fiscal Folly, Zurzuvae Dilemma SAGE Therapeutics, Inc. (SAGE) Q3 2023 Earnings Call Transcript Sage Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Sag...
ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD pr...
2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...
2023-11-20 00:24:09 ET Summary Biotech stocks have been heavily impacted by rising interest rates and the disruption caused by FTC-challenging acquisitions of biotechs. The equal-weight biotech ETF (XBI) has shown signs of a rebound after a prolonged downtrend, potentially due to ...
2023-11-10 06:57:27 ET Summary Sage Therapeutics' flagship product, Zurzuvae for PPD, faces market adoption challenges due to its controlled substance status. Increasing R&D expenses and a high burn rate raise concerns about Sage's long-term financial sustainability. Sage'...
2023-11-08 07:40:46 ET More on Biogen Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley 21st Annual ...
2023-11-07 18:02:21 ET It wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. Its price tumbled by nearly 5% as the market digested the healthcare company's third-quarter results. This was on a day when stocks were generally performing...
News, Short Squeeze, Breakout and More Instantly...
Sage Therapeutics Inc. Company Name:
SAGE Stock Symbol:
NASDAQ Market:
Sage Therapeutics Inc. Website:
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of Mama’s Creations Inc (...
Sage Therapeutics, Inc. (NASDAQ:SAGE) shares are trading lower on Tuesday. The company eelier announced results from its Phase 2 Huntington’s...
The SURVEYOR Study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery ( HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease (HD) prior to any treatment ...